NCT03463460View on ClinicalTrials.gov

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Thymic Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Sunitinib Malate

Given PO

Trial Locations (3)

33612

RECRUITING

Moffitt Cancer Center, Tampa

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

46202

RECRUITING

Indiana University, Indianapolis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dwight Owen

OTHER